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Abstract. Inherited hemoglobin disorders, including beta-thalassemia (BT) and sickle-cell 
disease (SCD), are the most common monogenic diseases worldwide, with a global carrier 
frequency of over 5%.
1
 With migration, they are becoming more common worldwide, making 
their management and care an increasing concern for health care systems.  
BT is characterized by an imbalance in the α/β-globin chain ratio, ineffective erythropoiesis, 
chronic hemolytic anemia, and compensatory hemopoietic expansion.
1
 Globally, there are over 
25,000 births each year with transfusion-dependent thalassemia (TDT). The currently available 
treatment for TDT is lifelong transfusions and iron chelation therapy or allogenic bone marrow 
transplantation as a curative option. SCD affects 300 million people worldwide
2
 and severely 
impacts the quality of life of patients who experience unpredictable, recurrent acute and chronic 
severe pain, stroke, infections, pulmonary disease, kidney disease, retinopathy, and other 
complications. While survival has been dramatically extended, quality of life is markedly 
reduced by disease- and treatment-associated morbidity.  
The development of safe, tissue-specific and efficient vectors, and efficient gene-editing 
technologies has led to the development of several gene therapy trials for BT and SCD. However, 
the complexity of the approach presents its hurdles. Fundamental factors at play include the 
requirement for myeloablation on a patient with benign disease, the age of the patient, and the 
consequent bone marrow microenvironment. A successful path from proof-of-concept studies to 
commercialization must render gene therapy a sustainable and accessible approach for a large 
number of patients. Furthermore, the cost of these therapies is a considerable challenge for the 
health care system. While new promising therapeutic options are emerging,
3,4
 and many others 
are on the pipeline,
5
 gene therapy can potentially cure patients. We herein provide an overview 
of the most recent, likely potentially curative therapies for hemoglobinopathies and a summary 
of the challenges that these approaches entail. 
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Bone Marrow Transplantation (BMT). One of the most recurring statements in the literature about 
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hematopoietic stem cell transplantation (HSCT) in 
thalassemia is “Allogenic bone marrow transplantation 
is the only available curative treatment for thalassemia 
major.” This approach is rooted in the Italian 
experience of the early 1980s at the transplant center of 
Pesaro, where throughout the 1980s and early 1990s, 
more than 1000 thalassemia major (TM) patients 
received transplants, and the center reported a 20-year 
probability of Thalassemia-free survival of 73% in 900 
consecutive transplanted patients.
6
 
More than 35 years have passed since the first TM 
patient underwent an allogeneic BM transplantation. 
Since the pioneering Pesaro experience, the curative 
role of BM transplantation in TM has been well 
established, and other European Bone Marrow 
Transplant (EBMT) centers have routinely performed 
this therapy.  
Indeed, in a retrospective non-interventional study, 
data analyzed from the EBMT registry database on 
1493 consecutive patients with TM transplanted 
between 1 January 2000 and 31 December 2010. The 
2-year overall survival (OS) and event-free survival 
(EFS) were 88±1% and 81±1%, respectively, after a 
median observation period of 2 years. OS and EFS 
were 90%, 81% and 93% (P<0.001), and 82%, 76%, 
and 85% (P=0.003) in patients who had received bone 
marrow, peripheral blood, or cord blood (alone or 
combined), respectively.
7
 
The decision to undergo a curative but potentially 
fatal treatment should be taken with an assessment of 
transplantation-related mortality (TRM). The Pesaro 
risk assessment (for a pediatric population) was 
developed in the early 1990s.
8
 This assessment 
stratifies the outcome of transplantation in three classes 
on the basis of hepatomegaly, portal fibrosis, and 
irregular chelation history.
6
 According to these risk 
factors, patients were categorized into three risk 
classes: Class 1 patients, who had none of these 
adverse risk factors, class 2 patients, who had one or 
two adverse risk factors and class 3 patients, who had 
all three. The thalassemia-free survival (TFS) was 
respectively 85-90%, 80% and 65-70%, while the 
transplant-related mortality (TRM) positively increased 
between classes 1, 2, and 3.
9
 
Taking these results into consideration, it is 
mandatory to offer an HSCT to a young TM patient 
with a matched sibling donor before the development 
of iron overload and iron tissue damage. Of note, all 
the gene therapy clinical trials have as exclusion 
criteria the presence of a matched sibling donor (MSD). 
The rational of bone marrow transplantation in a 
TM patient is to restore the tissue's capability of 
producing functional hemoglobin, and that can be 
achieved even with the coexistence of donor and 
recipient hematopoietic stem cells. In fact, in 
approximately 10% of patients, a condition of 
persistent mixed chimerism in which the donor 
hematopoiesis maintain the potential to correct the 
phenotype of the disease was described. On the other 
hand, it is vital to minimize the risk of graft-versus-
host disease (GVHD), since the immunologic effect of 
the transplant is unnecessary in a non-malignant 
disease such as thalassemia. 
According to the retrospective EBMT survey 
concerning the HLA matching of transplant recipients, 
1061 (71.1%) HSCT were performed using HLA-
identical sibling donors, 127 (8.5%) from another 
HLA-matched relative, 57 (3.8%) from an unmatched 
relative and 210 (14.1%) from a matched unrelated 
donor.
7
 This significant disproportion of donor sources 
is due to the fact that MSD transplants give the safest 
outcome with a 2-year OS of 91%, compared to 88% of 
matched family donors and 77% of matched unrelated 
donors. 
In a recent survey, Li et al. analyzed data about 
BMT in children and young adults with TM comparing 
the use of alternative donors and HLA-matched related 
donor in 3 geographic regions: China, India, and the 
United States. They reported that the 5-year 
probabilities of OS after HLA-matched relative, HLA-
mismatched relative, HLA-matched unrelated, and 
HLA-mismatched unrelated donor transplants were 
89%, 73%, 87% and 83%, respectively. The 5-year 
probabilities of EFS after HLA-matched relative, HLA-
mismatched relative, HLA-matched unrelated, and 
HLA-mismatched unrelated donor transplants were 
86%, 70% and 82%, 78%, respectively.
10
 This report is 
the first demonstrating comparable event-free and 
overall survival after HLA-matched related and HLA-
matched unrelated donor transplantation.  
BM transplantation was the only approved curative 
treatment for TM patient until June 2019, when the 
first gene therapy product, Zynteglo, was approved by 
the European Medicine Agency (EMA) for TDT 
patients who do not entirely lack beta-globin and who 
are eligible for stem cell transplantation but do not 
have a matching related donor.
11
 Of note, the 
availability of a suitable donor, together with patient 
fitness, are the main limitations to the broader use of 
HSCT. For this reason, there is a need to reduce the 
toxicity of HSCT, investigate new conditioning 
strategies, or improve and extend the autologous gene 
therapy approach also to the most severe cases. 
 
Clinical Trials Based on Gene Therapy and Gene 
Editing. Currently, a growing number of clinical trials 
for hemoglobinopathies are investigating the safety and 
efficacy of gene addition and gene editing based 
technologies to rescue hemoglobin synthesis in beta-
globinopathies. The first and longer-dated include trials 
indicated for the cure of beta-thalassemia as well as 
sickle cell disease via beta or gamma-globin gene 
addition, while the latter is mostly aimed at the cure of 
SCD via reactivation of fetal hemoglobin. The first 
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gene addition-based trial that led to cure in a 
beta0/betaE patient was reported in 2010,
12
 and since 
then, roughly 50 patients with BT and more than 20 
patients with SCD have been treated, and the related 
outcomes have been reported. The data published or 
communicated on the trials were obtained with four 
different lentiviral vectors: HPV569, later implemented 
as Lentiglobin BB305,
13
 employed by bluebird bio 
(formerly Genetix Pharmaceuticals); GLOBE,
14,15
 
employed by IRCCS San Raffaele, Italy; RVT-1801, 
employed by CCHMC, Cincinnati, USA (presented at 
the 22
nd
 ASCGT meeting in 2019), and TNS9.3.55,
16
 
employed by Memorial Sloan Kettering Cancer Center 
NY, USA. This trial (NCT01639690) was subsequently 
halted, and only one patient (out of 4 treated) had a 
significant decrease in transfusion requirements. An 
additional trial has been initiated by UCLA, using the 
AS3-FB vector,
17
 but no data related to patients’ 
outcome has been released so far. Table 1 lists the trial 
identifiers as well as the specifics of vectors and 
regimens employed in each trial. The significant 
challenges for these trials relate to two major 
determinants intrinsic to hemoglobinopathies: the 
severity of the hemoglobin defect in BT (i.e., beta0/0 
genotype being the most challenging to correct) as well 
as the disease progression for both BT and SCD. Initial 
trials, focused on adult patients with a beta+/+ or 
beta+/0 BT, had a fair degree of success, where 
patients became mostly transfusion independent even 
with suboptimal level (less than two copies per 
genome) of lentiviral integration or vector copy 
number (VCN) (NCT01745120 and NCT02151526). 
This level of integration proved to be unsuccessful at 
achieving transfusion independence for most of the 
adult patients affected by BT due to a beta0/0 
genotype.
18
 Therefore, subsequent trials have aimed at 
optimizing transduction protocols to obtain higher 
VCN (roughly 3-4 copies) in the drug product (DP), 
which indicates a patient hematopoietic stem cell 
(HSC) transduced with the lentiglobin vector, and 
maximizing transgenic chimerism, which indicates the 
proportion of HSC successfully transduced and 
engrafted. Patients with beta0/0 BT and SCD have 
benefited from the new transduction regimens, 
achieving hemoglobin (Hb) levels that do not require 
transfusion and therefore are considered curative 
(NCT02906202 and groups B and C of NTC02140554, 
see Table 1 for details). In light of these results, EMA 
recently approved bluebird bio’s Zintheglo, the first 
drug for gene therapy in TDT, in Europe. We learned 
that disease progression, hence the age of a patient, can 
greatly affect the outcome of gene therapy. Actually, 
the trial conducted in Italy (NCT02453477), using 
GLOBE, showed that the same protocol produced the 
best outcome in the youngest cohort (pediatric), while 
it was progressively less successful for the middle and 
oldest ones.
19
 More data on the pediatric population 
will be necessary to better elucidate the correlation 
between curative outcome and age. 
Additionally, in the first seven subjects with SCD 
(NTC02140554-group A), for whom BM-derived HSC 
were utilized, the median expression of vector-derived 
hemoglobin was only 0.4 g/dL (range 0.1 to 1 g/dL). 
Both cases suggest that the BM environment in 
hemoglobinopathies is not fully understood, and its 
physiology might be progressively altered by disease 
progression. Better results were achieved by the 
procurement of HSC from peripheral blood via 
apheresis, using improved mobilization practices, as 
discussed in the section that follows.  
 
Table 1 
Trial identifier 
Hemoglobinopathy/ 
number of patients 
Myeloablative 
regimen 
Mobilization 
protocol 
CD34+ 
infused 
(million/kg) 
Vector 
VCN in 
DP 
(Median) 
Sponsor/ Center 
NCT02186418 SCD (2) IV Melphalan 
BM harvest/ 
Plerixafor 
1 and 6.9 RVT1801 0.3 Aruvant/ CCHMC 
NCT02453477 
BT (9, of which 6 
pediatric) 
Treosulfan 
and Thiotepa 
G-CSF and 
Plerixafor 
19.5 (I.O. 
infusion) 
GLOBE 0.93 
San Raffaele Telethon 
Institute for Gene Therapy 
(SR-TIGET) Italy 
NCT01745120 
(HGB-204) 
BT (18 as of 4/2018) Busulfan 
G-CSF and 
Plerixafor 
8.1 BB305 0.7 
bluebird bio (multicenter, 6 
sites) 
NCT02151526 
(HGB-205) 
BT and SCD (4 as of 
4/2018) 
Busulfan 
(adjusted 
based on daily 
PK 
monitoring) 
G-CSF and 
Plerixafor 
(after 3 
months of 
enhanced 
transfusion) 
10.5 BB305 1.3 
bluebird bio (Necker 
Children’s Hospital in 
Paris) 
NCT02140554 
(HGB-206) 3 
groups: A, B, C 
SCD (7, A); (2, B); and 
(9, C) 
Busulfan 
BM harvest 
(A, B)/ 
Plerixafor (C) 
2.1 (A) 
2.7 (B) 
6.5 (C) 
BB305 
0.6 (A) 
3.1 (B) 
3.8 (C) 
bluebird bio (USA) 
NCT02906202 
(HGB 207) 
Non beta0/0 BT 
including pediatric (16) 
Busulfan 
G-CSF and 
Plerixafor 
NA BB305 3.1 
bluebird bio (international, 
multicenter) 
NCT03207009 
(HGB 212) 
beta0/0 BT (3) Busulfan 
G-CSF and 
Plerixafor 
NA BB305 NA 
bluebird bio (international, 
multicenter) 
 
  www.mjhid.org Mediterr J Hematol Infect Dis 2019; 11; e2019067                                                         Pag. 4 / 12 
 
The first clinical data based on a gene-editing 
approach were recently communicated for the clinical 
trial NCT03282656 for severe SCD (ASH 2018), 
which has been conducted at the Boston Children’s 
Hospital, MA, by bluebird bio. As for most of the gene 
addition studies above mentioned, this pilot trial uses 
Plerixafor to mobilize patients’ HSC and a busulfan 
regimen for conditioning. The first three patients 
presented at ASH 2018 were infused with a drug 
product (HSC count: from 3.3 to 6.7 X 10^6/kg 
weight) that had a VCN between 3.25 and 5. The drug 
product was transduced (over 90% rate) with 
BCH_BB-LCRshRNA (miR),
13
 a lentiviral vector that 
carries a short hairpin RNA targeting BCL11A, a 
known repressor of gamma-globin expression.
20
 The 
first patient treated and followed for six months 
presented a 24% increase in HbF, a high number of F 
expressing cells in circulation (72%), a considerable 
reduction in reticulocytosis as well early mitigation of 
some of the cellular phenotype of SCD. Enrollment for 
this trial is still active and will involve a total of 7 
patients.  
Since naturally-occurring deletional mutations of 
the binding site of BCL11A in the gamma-globin 
promoter have been found to be associated with cases 
of high persistence of fetal hemoglobin (HPFH), this 
very same deletion has been the target of the newest 
gene-editing approaches for SCD. Two trials, enrolling 
patients in more than one site within the US, 
NCT03745287 and NCT03653247, are been conducted 
by CRISPR Therapeutics and Bioverativ (Sanofi), 
respectively.  
Although based on the same target, the CRISPR 
therapeutics approach relies on the use of 
CRISPR/CAS9 to edit patients’ HSC, while Sanofi’s 
approach relies on the use of a zinc-finger nuclease. An 
additional trial by Sangamo, NCT03432364, also uses 
a zinc-finger nuclease approach to target the enhancer 
of BCL11A, although this treatment is indicated for BT. 
Preliminary results, presented by Sangamo at ASCGT 
2019, showed successful gene editing of peripheral 
white blood cells collected from the first treated patient, 
a beta0/0 BT case, an increase of fetal Hb levels, and 
stable total Hb values around 9g/dL at 50 days from the 
infusion. Longer follow-up periods for all these most 
recent studies are needed to further elucidate the extent 
of the success of the gene-editing technology for 
hemoglobinopathies. 
 
Conditioning in Clinical Trials and New Preclinical 
Development. The conditioning regimen for 
hemoglobinopathies does not include drugs with 
specific antitumor effects, given the non-malignant 
nature of these diseases.
21
 Nevertheless, to achieve 
stable engraftment, patients receive chemotherapy that 
aims to make space, eliminating an extremely 
proliferating marrow with erythroid hyperplasia and 
favor engraftment of HSC.
22,23
  
Data from reduced-intensity allogeneic 
transplantation in limited clinical series show that the 
achievement of stable donor engraftment is difficult in 
immunocompetent patients with 
hemoglobinopathies.
24,25
 Therefore, patients with BT 
and SCD need more intensive myeloablative 
conditioning regimens in order to reduce the risk of 
graft failure.
23
 Myeloablative conditioning is associated 
with short- and long-term toxicity in hematopoietic and 
non-hematopoietic tissues, including cancer and 
infertility and gonadal failure, particularly among 
females.
26
 The ideal regimen should combine an 
efficient depletion of HSC and minimized toxicity. 
Non-myeloablative reduced-intensity conditioning, 
based on busulfan at a total dose of 8 mg/kg, has been 
used in the gene addition trial (NCT01639690) at 
Memorial Sloan Kettering Cancer Center
27
 and resulted 
in insufficient engraftment of gene-marked cells and 
minimal clinical benefit.
28
 
In two phase 1/2 GT trials 
(NCT01745120 and NCT02151526) for TDT with 
LentiGlobin BB305 vector, myeloablative conditioning 
with busulfan as a single agent was used. A dose 
adjustment was performed to achieve appropriately 
targeted drug exposure. The average daily plasma 
busulfan area-under-the-curve values ranged from 3029 
to 4714 μM per minute in HGB-204 (estimated values) 
and from 4670 to 5212 μM per minute in HGB-205 
(actual values). Among the 22 treated patients, 9 
serious adverse events (SAE) were reported, including 
two episodes of veno-occlusive liver disease attributed 
to busulfan conditioning.
18
 Busulfan was also used for 
SCD patients in several trials (NCT02151526, 
NCT03282656, NCT02247843) with mixed results.
29
 
The phase 1/2 GT trial for TDT at IRCCS San 
Raffaele in Milan, used myeloablative conditioning 
with treosulfan–thiotepa, given their reduced 
extramedullary toxicity compared to busulfan. 
Chemotherapy-related toxicity was mild, and 5 SAE of 
infectious nature were reported and resolved. Neither 
veno-occlusive disease nor hepatic toxicity was 
observed.
19
 Most recently, preliminary results from a 
reduced-intensity conditioning (RIC) phase 1/2 pilot 
study on gene transfer for SCD were presented.
30
 For 
this trial, a single dose of melphalan is used as the 
conditioning regimen, while patients’ HSC are 
corrected using a γ-globin based lentiviral vector 
(RVT1801; NCT02186418). Results from this trial 
showed excellent safety, feasibility, with minimal post-
transplant toxicity, rapid count recovery, and sustained 
stable genetically modified cells in peripheral blood 
and bone marrow. 
Although autologous HSCT using genetically 
corrected cells would avoid the risk of graft-versus-
host disease (GVHD), the genotoxicity of conditioning 
remains a substantial barrier to the development of this 
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approach in non-malignant disorders. The toxicities of 
conditioning lessen the willingness of patients and 
healthcare providers to consider this therapy. Novel 
strategies that aim to reduce regimen-related toxicity, 
remaining on the other hand sufficiently myeloablative, 
are based on the use of antibodies that specifically 
target HSC and other hematopoietic cells in the bone 
marrow niche, sparing non-hematopoietic cells.
31,32
 If 
proof of safety and efficacy stands, these new regimens 
will satisfy the need for reduction of morbidity and 
mortality related to the current conditioning regimens, 
mainly based on busulfan administration. 
In mice, immunotoxin CD45–saporin (SAP) allows 
high-level engraftment and multi-lineage repopulation 
of transplanted HSC without the need for 
chemotherapy or irradiation and enables efficient 
engraftment of donor cells and full correction of a 
sickle-cell anemia model.
31
 
The depletion of HSC can also be achieved using a 
c-kit (CD117) antibody, as its receptor is highly 
expressed on these cells. Binding of CD117 ligand is 
essential for hematopoiesis and self-renewal. The 
internalization of the receptor by antibody binding 
causes HSC failure. A CD117 antibody molecule 
conjugated with a non-genotoxic small toxin molecule 
can deplete more than 98% of human HSC in NSG 
mice, leaving intact T and B cells.
33
 Instead, the 
unconjugated antibody presents a much-reduced effect. 
The velocity of the internalization of the receptor and 
selectivity of the CD117 molecule makes this method 
an excellent candidate for gene-corrected BMT for 
hematopoietic conditions, like BT and SCD, preventing 
the systemic toxicity typical of irradiation and 
chemotherapy regimens.  
A clinical study, carried out at Stanford 
(NCT02963064), utilizes this very strategy to condition 
patients with severe combined immunodeficiency 
disease prior to HSCT. This study aims at 
demonstrating the safety and efficacy of AMG191, a 
CD117 conjugated antibody given intravenously in one 
dose, followed by infusion of donor CD34+CD90+ 
HSC. This purified fraction of HSC that can be isolated 
by flow cytometry has been shown to possess the stem-
like quality necessary to repopulate the BM in long 
term studies in nonhuman primates.
34
 Patients that 
undergo this procedure receive 1X106 CD34+CD90+ 
cells/kg, a much lesser dose than that one used when 
the CD34 marker alone is selected. The antibody 
clearance can be monitored via PK study to establish 
the best time for the infusion of donor cells without 
compromising their chance to engraft the BM niche. 
This protocol includes subjects with a poor graft from 
previous HSCT, indicating that this could be performed 
in patients whose prior BMT has not succeeded with 
chemotherapy agents. If successfully and safely applied 
to patients with hemoglobinopathies, this technology 
could positively impact not only patients’ health, by 
eliminating the myeloablation related toxicity, but also 
limit the cost of gene therapy, by limiting the number 
of cells that needs to be corrected. 
  
CD34+ Hematopoietic Progenitor Cells 
Mobilization. Peripheral stem cells are commonly 
used for transplantation and have replaced bone 
marrow as a source of HSC in most transplants, 
especially in the autologous setting.
35
 Granulocyte-
colony stimulating factor (G-CSF) is the standard agent 
to mobilize hematopoietic stem and progenitor cells 
(HSPC) for transplantation. However, peculiar features 
of hemoglobinopathies, namely splenomegaly and 
thrombophilia state, may represent risk factors for 
adverse events. G-CSF-related enlargements of the 
spleen, rarely resulting in splenic rupture,
36-38
 and 
thrombotic events
39
 have been reported. 
Moreover, in adult thalassemia patients iron-
overload and consequent oxidative stress, the 
suppressive effect of long-term transfusions and 
chelation on the stem cell compartment, and the "aged" 
stem cells, could compromise the safety and success of 
HSC procurement.
40
 Also, in SCD, the use of G-CSF 
has been associated with severe and life-threatening 
vaso-occlusive complications.
41,42
 G-CSF induces an 
increase in white blood cells count, neutrophils, 
endothelial cells, platelets, and coagulation activation, 
all mechanisms that contribute to the vaso-occlusive 
crisis. 
Among the other compounds available, Plerixafor 
represents a good alternative. Plerixafor is a bicyclam 
molecule that selectively and reversibly prevents the 
binding of stromal-derived factor-1 (SDF-1) to 
chemokine CXC-receptor-4 (CXCR4) on HSPC, 
inducing their mobilization.
43
 Plerixafor has proved to 
be safe and effective in mobilizing HSC in thalassemia 
patients.
18,19,44
  
It has been shown that Plerixafor and G-CSF 
mobilize different primitive HSC populations, either in 
thalassemia patients with thalassemia or healthy donors. 
Plerixafor-mobilized cells have a “stemness” signature 
compared to G-CSF mobilized cells, and the combined 
use of the two agents attenuates this “stemness." 
Furthermore, Plerixafor-mobilized HSC possess the 
highest ability to home to hematopoietic niches and 
engraft in immunodeficient mice, and their global gene 
expression signature highlights their superior in vivo 
reconstitution activity.
45
 
Currently, several phase 1 and 2 trials are evaluating 
the safety and efficacy in collecting a sufficient number 
of HSC with Plerixafor in SCD patients 
(NCT02989701, NCT03226691, NCT02193191, 
NCT02212535, NCT02140554). Lagresle-Peyrou’s 
group published the results of a French trial; no adverse 
events were observed administrating Plerixafor in a 
single-dose of 240 mcg/kg in three patients who had 
discontinued hydroxyurea (HU). Moreover, with single 
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apheresis, they were able to collect a high number of 
HSC.
46
 Interim results from a Memorial Sloan 
Kettering Cancer Center trial with Plerixafor at 
escalating dose reported data on 15 patients. Ten were 
on HU and one on chronic transfusion regimen. Two 
serious adverse events (pain crisis) have been observed 
at 80 and 240 mcg/kg of Plerixafor, and only 33-50% 
of patients, according to different doses, reached the 
target yield of HSC.
47
 Most recent data on group C 
from the HGB-206 study (NCT02140554) show that 
mobilization was effective in SCD patients with 
Plerixafor at the dose of 240 mcg/kg. No life-
threatening VOCs after Plerixafor mobilization have 
been reported.
48
 
Three main considerations can be drawn from the 
studies on conditioning conducted thus far. One relates 
to HU administration prior to the mobilization. HU 
reduces the amount of circulating CD34+,
49
 is 
associated with myelosuppression, and did not show 
any beneficial effect in thalassemia patients.
40,50
 In the 
French trial, patients discontinued HU 3 months before 
the mobilization. However, in the New York trial, no 
association was observed between HU and the peak of 
HSC. The second concerns the maintenance of HbS 
levels>30% in order to prevent the vaso-occlusive 
crisis. In the French trial (NTC02212535), during the 
three months before the mobilization, patients 
underwent a transfusion or erythro-exchange 
program.
46
 The third is the timing of apheresis. The 
peak of circulating HSC in SCD patients have been 
observed at 3-6 hours, earlier compared to healthy 
donors (6-12 hours)
51
 in whom apheresis is 
recommended to start at 11 hours after Plerixafor 
administration. 
 
From Clinical Trials to Drug Commercialization, 
the Challenges of Pivotal GT Studies. Because of 
their monogenetic etiology, both BT and SCD are 
attractive targets for curative approaches as gene 
addition and gene editing. 
Gene addition strategies have significantly 
improved over the past ten years and have provided the 
most successful results thus far. Although these 
approaches may seem straightforward given the single 
gene defect and defined cell target, there are still 
several hurdles that can impact their success, as 
previously reported.
52
 
One of the most relevant challenges is to guarantee 
a level of functional beta-globin protein expression that 
can rescue the complete lack of endogenous adult 
hemoglobin protein, like that seen in patients with 
beta0/0 BT. The constructs employed in clinical trials 
utilize large genomic regulatory elements that are 
essential to express high and tissue-specific expression 
of the gene of interest, and they are engineered to 
maximize their safety. The need for such large 
constructs on the other side can affect the viral 
assembly and entry, impacting the yield of viral 
particles that can be functionally assembled during 
manufacturing, and limiting the number of particles 
that can effectively enter the target HSC, respectively.  
Viral vector-based gene therapy has become 
commonplace in both the laboratory and the clinic, and 
it is rapidly evolving towards becoming a curative 
treatment option. Currently, several products are under 
clinical development, and the European Medicine 
Agency recently approved the first lentiviral product 
(Zynteglo, based on BB305) for gene addition based 
therapy for BT. The transition from clinical 
development to commercialization adds another layer 
of complexity to the picture. Thus, the most pressing 
concern becomes no longer to make safe, functional 
lentiviral vectors solely, but to also refine current 
processes in order to achieve both yield and quality 
while reducing costs, processing times, and risks to 
support research, development, and commercialization.  
lentivirus-based gene and cell therapy products 
were estimated in 2017 to cost in the range of U.S. 
$500,000–1,000,000 per patient,53 a third of which 
pertains to the lentivirus manufacturing process itself. 
Access to gene therapy to a large number of patients 
with a hemoglobinopathy is highly dependent on a 
reliable high-scale lentiviral production. The 
implementation of scalable vector production protocols 
is indispensable to fulfill not only the demand of 
academic and hospital institutions, but also of the 
industry, which is incentivized to satisfy the upsurge of 
requests for safe and efficient products.  
 
Lentiviral Vectors Manufacturing. Lentiviral vector 
manufacturing technologies are based primarily on 
fully transient, adherent processes. These 2-dimension 
methods are tedious, time-consuming, and difficult to 
scale up, with carry-associated issues of process 
handling, results inconsistency, and high costs. Small-
scale productions for R&D purposes are performed 
transfecting adherent 293T cells grown in plasticware 
(Petri dishes, T-flasks, Cell Factories, Cell Stacks, or 
HYPERFlask) in the presence of either PEI or Calcium 
Phosphate (CaPho).
54,55
 
Conversely, large-scale vector manufacturing 
generally requires a direct scale-up from small-scale 
systems to increase volumes and titers, and reduce 
variability. This can be accomplished by using 
alternative culture devices (e.g., roller bottles, multi 
tray cell factories, or microcarriers in stirred tanks) that 
provide extended anchorage surface for adherent 293T 
cells. Valkama AJ et al.
56
 demonstrated how 
parameters, such as cell density, pH levels, and 
transfection methods, play a delicate role for large-
scale lentiviral production. In their study, they use 
PALL iCELLis, a compact fixed-bed bioreactor with 
an integrated perfusion system, comparing yields 
achieved with either CaPho precipitation or PEI 
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transfection methods, within a range of pH and under 
glucose and lactate concentration monitoring. In both 
transfection methods, they confirmed the critical role 
of cell density and pH in the efficiency of 
productivity,
57
 showing higher production at high cell-
density and mildly acidic pH, with vp cm–2 (vp= viral 
particle) between 1.31E+08 and 4.85E+08 using 
iCELLis Nano fixed-bed bioreactors. 
To overcome the need for traditional large-scale 
technologies in lentiviral production, some 
investigators have engineered novel suspension-
adapted cell lines.
58
 Although there are no established 
and standardized methods based on this suspension 
approach with a Good Manufacturing Practices (GMP) 
grade approval, several studies are ongoing, aiming to 
fill the demand for a robust supply chain for GMP 
materials.  
Suspension-adapted cell lines can easily grow at 
high cell densities in a packed-bed bioreactor, stirred 
tanks, or Erlenmeyer flasks agitated on orbital shakers, 
which require minimum handling or supplementary 
laboratory equipment.
55
 Several cell lines (293T, 
293FT, and 293SF-3F6) have already been used for the 
purpose, through a modification that allows growth in 
suspension in chemically defined media (Freestyle 293 
and F17, Invitrogen; HyQSFM4TransFx293).
58,59
 
Suspension-adapted cell lines grow promptly rendering, 
thus their maintenance and propagation much easier 
than that of adherently growing cells. Another 
advantage of the use of this system in clinical 
manufacturing is the lack of requirement for bovine 
serum and animal origin components in the culture 
media, which decreases the risk of contamination by 
adventitious agents. 
The preferential vessel for large-scale lentiviral 
production using suspension-adapted cells is a 
bioreactor. In this type of system, DNA precipitation 
using calcium phosphate is expected to be less 
effective for transfecting suspension cells because of 
continuous culture stirring. Other transfection agents 
like cationic polymers are used instead. Using linear or 
branched 25-kDa PEI, Durocher et al. achieved the 
highest transfection efficiency in 293T and 293-
EBNA1 cells, leading to 75% of transfected cells using 
a green fluorescent protein (GFP) reporter plasmid.
60
 
McCarron et colleagues were able to reach yields of up 
to 10
9
 TU/mL (TU= transducing units) using a packed-
bed bioreactor system, suggesting a more significant 
potential on the basis that the total packed-bed surface 
area is 18m
2
, which is equivalent to approximately 28 
standard 10-layer cell factories.
61
 
The viral supernatant is collected from suspension-
adapted cells in the bioreactor by anion exchange 
chromatography. The eluted material can then be 
concentrated using tangential flow filtration (TFF), and 
the vector may then be diafiltered into its final 
formulation buffer.
62
 
More recently, developed protocols for lentiviral 
manufacturing employ hollow fiber bioreactor, 
suspension culture processes, and the implementation 
of stable producer cell lines. The use of stable producer 
cell lines allows to further scale-up production, having 
the advantage to remove any undesirable process-
derived contaminant, such as plasmid or host cell DNA 
or host cell proteins.
63
 The biomedical industry is the 
driving force to make the use of all these technologies 
accessible for large-scale platforms in terms of 
manufacturing, costs, and GMP-compliance. Some of 
these innovative technologies were presented last May 
at the 22
nd
 ASCGT meeting. Two independent 
companies showed the generation of a suspension-
adapted cell line GMP-compliant for lentiviral 
packaging using an inducible Tet system,
64
 and 
production of lentiviruses up to 200L in PALL 
iCELLis500, reaching 80.1% transduction efficiency in 
T-cells using a Multiplicity of Infection MOI=4,
65
 
respectively. 
 
HCS Transduction and Handling. Downstream the 
lentiviral production per se, the manufacturing of the 
drug product (DP), which consists of patients’ HSC 
corrected with a lentivirus, represents another 
benchmark for innovative and unconventional 
protocols that aim to make the process more efficient 
and scalable. Efficient HSC transduction requires 
highly concentrated and purified lentiviral particles and, 
in diseases like beta0/0 BT, in which a higher number 
of integrations are necessary to achieve curative 
outcomes, integration of large transgenic cassette can 
be particularly challenging. Resistance to infection has 
been attributed to the quiescent (G0) phase and the 
innate immune defenses against viral transduction.
66
 
Given the need to achieve optimal integration in the DP 
that guarantees curative effects without compromising 
genome safety, several experimental transduction 
protocols, and agents to enhance/modulate lentiviral 
gene transfer yield have been developed. The necessity 
to make the manufacturing of the DP as consistent and 
reproducible as possible has been driving force for 
these technologies. 
Transduction efficiency can be improved, even at 
low MOIs, using small molecules like cationic-
liposomes, polycations, or small peptides as adjuvant-
enhancer of transduction. For over a decade, cationic 
polymers such as hexadimethrine bromide (Polybrene) 
have been employed in laboratory-based protocols to 
neutralize the nonspecific electrostatic interactions 
between virus and target cell.
67,68
 Due to its negative 
effect on cell growth and viability, polybrene is not 
indicated for clinical use. Therefore, new molecules 
have been engineered to promote vector-cell contacts 
similarly. Balancing safety and transduction efficiency 
has shown to be pivotal in the process of providing 
new adjuvants. More recently, Vectofusin-1,
69
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protamine sulfate,
70
 and fibronectin fragments
71
 have 
shown to increase transduction efficiency by 
facilitating adhesion and fusion between the viral cap 
side and the cell membrane. 
LentiBOOST
TM
 reagent, a large nonionic 
amphiphilic molecule (poloxamer), has been 
extensively used as a transduction enhancer, with 
greater activity and better safety profile than similar 
known nonionic molecules.
72
 Human peripheral blood-
derived CD34+ HSC transduced with standard MOI of 
10, and LentiBOOST
TM
 show increased gene 
expression and VCN proportional to adjuvant 
concentration with unaltered viability. The use of 
LentiBOOST
TM
 is compatible with spinoculation 
protocols, and its use in combination with protamine 
sulfate shows an addictive effect.
73
 Moreover, the use 
of RetroNectin and LentiBOOST
TM
 in human HSC 
transduction concurrently decrease electrostatic 
interactions and promote either adhesion/fusion and 
integration.
74
 
Prostaglandin E2 (PGE2) is a molecule that 
enhances transduction prior to nuclear entry and 
integration, possibly by interfering in the endocytosis-
dependent pathways.
75
 While initially intended as an 
anti-apoptotic agent in experiments on HSC, 
prestimulation with PGE2 surprisingly showed a ~1.5 
fold increase of VCN, both in vivo after 
xenotransplantation.
76
 Additionally, the combination of 
PGE2 and poloxamer synperonic F108 had a 
synergistic effect, increasing gene transfer in primitive 
HSC by ~10 fold in CD34+ HSPC with a globin-based 
lentivirus, which is highly desirable when high VCN is 
needed.  
Viral integration can also be facilitated by 
molecules that modulate intracellular processes, like 
Rapamacyn (Rapa). By inducing autophagy through 
allosteric inhibition, Rapa enhances post-binding 
endocytic events, increasing lentiviral entry, reverse 
transcription, and genomic integration.
77
 In mouse and 
human HSC, transduction with 5 to 20 μg/mL of Rapa 
significantly increase VCN, without loss of viability or 
engraftment (after transplantation). Furthermore, the 
role of Rapa on transcriptional and translational events 
could benefit the integration of lentiviruses by altering 
chromosomal accessibility.
78
 Cyclosporine H has 
recently been shown to efficiently enhance gene 
transfer bypassing the innate immune block that can 
interfere with efficient gene transfer in HSC. Unlike 
Cyclosporine A, which inhibits the host factor CypA, 
Cyclosporine H inhibits the interferon-induced 
transmembrane protein 3 (IFITM3) whose high 
expression potently restricts VSV-G pseudotyped LV 
entry.
79
 
A different approach, based on optimization of cell 
density, was used in a recent study, which suggested 
that cell-to-cell contact in a high-density (4e6/mL) cell 
culture may mimic bone marrow environment, 
allowing more efficient transduction. Ultimately, the 
combination of PGE2 and Poloxamer at high-density 
resulted in an even higher lentiviral transduction.
80
 
The handling of patients' HSC is just as sensitive, if 
not more, as the process of making GMP-grade 
lentiviral particles. Several instruments and trained 
personnel are needed to carry out the operations that 
involve HSC apheresis, CD34+ selection, transduction, 
and cryopreservation in conventional open 
environments. Even though individual automated 
instruments are currently used for each step of the 
process, the entire procedure could benefit from a fully 
automated closed-system that cuts procedure time, the 
risk associated with human error, and costs, which 
could have more drastic implications once the drug 
product reaches commercialization.  
A semi-automated immunogenetic selection system, 
the CliniMACS Plus by Miltenyi Biotec, is now 
approved in many countries for autologous CD34+ 
selection from mobilized apheresis products. The 
instrument uses a disposable tubing set that allows all 
significant steps of processing to happen in a closed 
system, thus minimizing the risk of contamination, a 
critical factor in cGMP compliance. This method has 
proved to be successful at reproducing consistent yields 
among many centers.
81
 An advanced version of it, the 
CliniMACS Prodigy, combines in one instrument the 
immunoseparation component with a chamber for 
further cell manipulation in a closed and fully 
automated system. The chamber has a built-in 
centrifuge and is temperature controllable from 4C – 
37C, making it also an incubator. Briefly, apheresis 
products undergo to immunomagnetic selection with 
nanobead-conjugated anti CD34 antibodies and buffer 
purification in a connected-sterile system with 
minimum need of operator attendance.
82
 This system is 
currently used in clinical studies for CAR-T 
manufacturing and allows after CD34 selection to 
perform lentiviral transduction, further purification and 
expansion (up to 12 days) within the same closed 
system. The end of the process sees the transduced 
target cells resuspended into the formulation buffer and 
potentially ready to be infused into the patient as drug 
product.
83
 
 
Summary and Conclusions. At the moment, the only 
available curative treatment for patients with BT and 
SCD is allogeneic HSCT. HLA matched sibling donor 
HSCT is now a well-proven therapy for SCD and BT; 
however, most patients (>75%) do not have access to 
this option due to lack of an available matched sibling. 
Alternative donor allogeneic HSCT using unrelated 
and haploidentical related donors that would be 
required for the cure in most patients with SCD and 
BTM remain limited by high rates of transplant-related 
mortality, GVHD, and graft rejection. Given the 
severity of BT and SCD and the shortcomings of 
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current curative treatment options, BT and SCD remain 
challenging diseases with a significant unmet medical 
need, which is even more aggravated in countries with 
poor access to health care. There is a clear need for 
potentially curative therapies that can circumvent or 
eliminate the deficiencies of current options, and 
significantly improve associated morbidity and 
mortality.  
Extensive progress has been made on gene therapy 
since its pioneering, making it a nearly available option 
for patients. Results from clinical trials of the last 
decade indicate that the use of lentiviral vectors can 
cure patients affected by hemoglobinopathies. At the 
moment, in order to correct the phenotype, many 
patients require high level of integrations per genome 
(~4) in a pancellular fashion. New challenges are 
represented by the need to transfer this technology 
from small to large-scale volumes, to launch its 
commercialization. As the medical field progresses 
with new and promising pharmacological therapeutic 
options, so does the urgency to find better regimens for 
mobilization and conditioning of patients for patients 
that opt to undergo gene therapy.  
Most importantly, the benefit of the new gene 
therapy approaches that are potentially curative would 
be reinforced if made accessible to a large number of 
patients and affordable for the health care system.  
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